Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
William D TapArun S SinghStephen Patrick AnthonyMike SterbaChao ZhangJohn H HealeyBartosz ChmielowskiAllen Lee CohnGeoffrey I ShapiroVicki L KeedyZev A WainbergIgor PuzanovGregory M CoteAndrew J WagnerFadi BraitehEric ShermanHenry H HsuCharles PeterfyHeather L GelhornXin YePaul SeversonBrian L WestPaul S LinSandra Tong-StarksenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These results offer insight into outcome patterns in cancers whose biology suggests use of a CSF1R inhibitor. Pexidartinib results in tumor regression in TGCT patients, providing prolonged control with an acceptable safety profile.